NASDAQ · MOLN
Molecular Partners AG financials
$3.90+1.04%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $5.5M | $8.4M | $189.6M | $10.2M |
| Gross profit | $0.00 | $5.5M | $8.4M | $189.6M | $10.2M |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$73.2M | -$67.8M | -$72.7M | $116.6M | -$70.0M |
| Net income | -$77.7M | -$59.8M | -$73.7M | $117.9M | -$70.0M |
| Net margin | — | −1087.4% | −880.7% | 62.2% | −683.7% |
| Diluted EPS | $-2.08 | $-1.76 | $-2.25 | $3.54 | $-2.26 |
| EBITDA | -$67.2M | -$65.1M | -$69.8M | $119.0M | -$67.2M |
| Operating cash flow | -$64.6M | -$65.6M | -$70.2M | $118.6M | -$99.8M |
| Free cash flow | -$65.5M | -$66.4M | -$70.8M | $117.4M | -$100.8M |
| Diluted shares | 37.3M | 34.0M | 32.8M | 33.3M | 31.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $104.2M | $70.7M | $80.0M | $95.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $201.6K | $0.00 | $0.00 | $0.00 |
| Total assets | $128.7M | $175.5M | $235.9M | $283.7M |
| Total liabilities | $27.4M | $18.7M | $26.1M | $29.3M |
| Shareholders' equity | $101.2M | $156.8M | $209.8M | $254.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology